ReviewPharmaceuticals (Basel, Switzerland)2021
Antimicrobial Properties of Antidepressants and Antipsychotics-Possibilities and Implications.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pharmaco-psychiatry and gut microbiome: a systematic review of effects of psychotropic drugs for bipolar disorder.Microbiology (Reading, England) · 2025Pooled it
- Local anesthetics as a tool for Staphylococcus spp. control: a systematic review.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Pooled it
- Drug-microbiome-host interactions: antimicrobial effects of non-antibiotic compounds.Nature reviews. Gastroenterology & hepatology · 2026Review
- Weight Gain During SSRI Therapy: The Potential Role of the Gut Microbiota-A Narrative Review and Mechanistic Hypothesis.Nutrients · 2026Review
- Psychotropic Drugs: A Promising Non-Antibiotic Agent to Combat Multi-Drug-Resistant Microorganisms.Drug development research · 2026Review
- Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus.npj antimicrobials and resistance · 2026Article
- Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus.Research square · 2026Article
- Desipramine treatment disrupts phagocytic and intracellular survival ofFrontiers in veterinary science · 2026Article
- Synergistic integration of exosomes and natural compounds in 3D-printed bioscaffolds: Revolutionizing diabetic wound healing through multifunctional therapeutic platforms.Iranian journal of basic medical sciences · 2026Review
- Beyond Antibiotics: Repurposing Non-Antibiotic Drugs as Novel Antibacterial Agents to Combat Resistance.International journal of molecular sciences · 2025Review
- Antibacterial Evaluation of Tricyclic Antidepressants AgainstPathogens (Basel, Switzerland) · 2025Article
- Heterocyclic Antidepressants with Antimicrobial and Fungicide Activity.Molecules (Basel, Switzerland) · 2025Review
- Tranylcypromine: a promising repurposed drug against Leishmaniases.Frontiers in microbiology · 2025Article
- Exploring the Antibiofilm Effect of Sertraline in Synergy withPharmaceuticals (Basel, Switzerland) · 2024Article
- The Repurposing of FDA-Approved Drugs as FtsZ Inhibitors againstMicroorganisms · 2024Article
- The Underlying Neurobiological Mechanisms of Psychosis: Focus on Neurotransmission Dysregulation, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction.Antioxidants (Basel, Switzerland) · 2024Review
- Mind, Mood and Microbiota-Gut-Brain Axis in Psychiatric Disorders.International journal of molecular sciences · 2024Review
- Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning.Frontiers in pharmacology · 2024Review
- Medication impact on oral health in schizophrenia.Medicina oral, patologia oral y cirugia bucal · 2024Article
- Flavonols in Action: Targeting Oxidative Stress and Neuroinflammation in Major Depressive Disorder.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spreading of antibiotic resistance is responsible annually for over 700,000 deaths worldwide, and the prevision is that this number will increase exponentially. The identification of new antimicrobial treatments is a challenge that requires scientists all over the world to collaborate. Developing new drugs is an extremely long and costly process, but it could be paralleled by drug repositioning. The latter aims at identifying new clinical targets of an "old" drug that has already been tested, approved, and even marketed. This approach is very intriguing as it could reduce costs and speed up approval timelines, since data from preclinical studies and on pharmacokinetics, pharmacodynamics, and toxicity are already available. Antidepressants and antipsychotics have been described to inhibit planktonic and sessile growth of different yeasts and bacteria. The main findings in the field are discussed in this critical review, along with the description of the possible microbial targets of these molecules. Considering their antimicrobial activity, the manuscript highlights important implications that the administration of antidepressants and antipsychotics may have on the gut microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.